Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > AACR

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 30, 2022 7:45pm

136 Views

Post# 34561040

RE:RE:RE:RE:RE:AACR

The corporate presentation states that phase Ib will include SORT1+ patients with many types of cancers. The only way to be sure at this point that a patient is SORT1+, is by doing a biopsy and immunostaining of the cancer tissue. So my understanding is that inclusion criteria will require overexpressing sortilin confirmed by a biopsy, even though on Clinicaltrials.gov, they only mention "selected patient populations". So I guess the selection will be made through biopsy and immunostaining.